Introduction
Boningmycin (BON), a new member of the bleomycin family, was isolated from the fermentation broth of Streptomyces verticillus var. pingyangensis n.sp in China [1] . BON has shown higher antitumor activities in vitro and in vivo than bleomycin at the same dose [2] . To further enhance the translational research of BON, the susceptibility of tumors cells to this drug must be evaluated with biomarkers in the clinic. Investigations using bleomycin have revealed several kinds of cellular proteins that mediate resistance, including bleomycin hydrolase (BLH) [3, 4] , DNA repair enzymes, antioxidant enzymes, membrane transport proteins and other cellular factors [5] [6] [7] [8] . NF-E2-related factor 2 (Nrf2), a transcription factor, is a pivotal factor in the induction of the cell defense system, primarily including the expression of a myriad of genes involved in -porters and other response pathways [9] . Nrf2 protein levels are regulated by several critical regulators, such as the binding partner Keap1 and autophagic pathway proteins p62, p53 and p21 [10] [11] [12] [13] . Accumulating evidence has indicated that Nrf2 also serves important roles in tumors. Nrf2 may be a driving force to promote tumorigenesis in several tumor types [14] . Constitutive activation of Nrf2 can result from point mutations in Keap1 in lung carcinoma [15] . Nrf2 can also mediate chemoresistance and radioresistance in tumor therapy, and several reports have demonstrated that Nrf2 mediates the resistance to doxorubicin, etoposide and DDP [16] [17] [18] , suggesting that Nrf2 compounds, such as luteolin (LUT) and brusatol, reveal effective suppression of tumor cells both in vitro and in vivo [19] [20] [21] . Nrf2 also influences the action and side effects of bleomy- [22] . Glutathione (GSH), a downstream product of Nrf2 signaling, markedly reduced bleomycin-induced damage [23, 24] . Nrf2 mRNA knockdown in A549 cells potentiated bleomycin action [16] . These observations may explain why A549 cells exhibited resistance to bleomycin in our previous study [3] . We hypothesized that Nrf2 also mediates the resistance to BON. In the present study, we have done
Materials and methods
Drugs and chemical agents BON at a purity > 95% was kindly provided by Prof Ru-xian CHEN from the Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences. BON was prepared in a 10 mmol/L solution with PBS buffer and stored at -20°C before use. Dimethyl sulfoxide (DMSO), 3-(4,5-dimethyl-2-thiazoyl) 2,5-diphenyl-2H-tetrazolium bromide (MTT), L-buthionine-sulfoximine (BSO), glutathione reduced ethyl ester (GSH-M), DDP and LUT were purchased from Sigma-Aldrich Chemical Inc (St Louis, Missouri, USA). BSO was dissolved with PBS buffer in a 150 mmol/L solution, and DDP was dissolved with DMSO in a 5 mmol/L solution. LUT was prepared in a 10 mmol/L solution with DMSO: ethanol (1:1, v/v) and stored at -20 °C before use. The culture media (DMEM and DMEM/F12), monochlorobimane (mBCI), 2,7-dichlorfluorescin diacetate (H2DCFDA), Lipofectamine™ 2000 and fetal bovine serum (FBS) were obtained from Invitrogen (Carlsbad, California, USA).
Cell lines and cell culture
Human hepatoblastoma HepG2 cells and human non-smallcell lung cancer A549 cells were purchased from Shanghai Cell Bank, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. HepG2 cells were cultured in DMEM media, and A549 cells were maintained in DMEM/F12 media. All media were supplemented with 10% FBS (v/v). All cultures were maintained in an incubator at 37 °C with 5% CO 2 in a Cell survival assay Cell viability was assessed by MTT assay. The cells were seeded into 96-well plates at a density of 3000 cells per well for 24 h and then treated with drugs for the indicated times. The MTT assay was performed as previously described [25] . The IC 50 value was calculated by nonlinear regression analysis.
Western blot analysis
Western blot analysis was performed as previously described [25] . The sources of primary antibodies were as follows. The antibodies against Nrf2 (ab62352) and NQO1 (ab119902) were purchased from Abcam (Abcam, Cambridge, UK). The antibodies against p53 (#2524S), HO-1 (#5061S) and (CST, Danvers, USA). The antibody against BLH (#MAB6200) was purchased from R&D Systems (Minnesota, USA). The secondary antibodies, horseradish peroxidase-linked anti-rabbit (#1705046) and anti-mouse (#1706516), were obtained from were used as a loading control.
RNA interference
Nrf2-and p53-specific siRNAs and scrambled siRNA were purchased from Life technology Inc (Carlsbad, California, USA). Cells were transfected with Lipofectamine 2000 accordof the siRNAs used for the transfection was 100 pmol. The transfected cells were incubated for 48 h, and the presence of the target protein was confirmed via Western blotting. The Nrf2 siRNA sequence was 5'-GAUGGAAUCUUUGAG-GUCAAGUCUA-3'. The p53 siRNA target sequence was 5'-GACTCCAGTGGTAATCTAC-3'.
Plasmid transfection
Nrf2 gene-carrying plasmids were constructed for this study -fected with the plasmids using Lipofectamine 2000 and then harvested after 48 h of transfection. The protein levels of Nrf2 were measured by Western blotting.
Cells were sonicated with ultrasonic fragmentation. The volume of the cell lysate was 0.5 mL, and protein concentrations were determined using a Bio-Rad protein assay. The intracellular glutathione concentration was quantified using a Total Glutathione Quantification Kit from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All procedures were followed according to the manufacturer's instructions. In brief, or the sample solutions was added to the working buffer. After 30 s, the absorbance was read at 412 nm (A1) and read once again (A2) after the cuvette was incubated at 25 °C for 5 min.
-
The cells were cultured in a 20-mm dish. After drug treatmBCI at 37 intracellular GSH concentration. The mean density from three independent experiments was quantified using Image-Pro Plus software.
Real-time quantitative reverse transcription-PCR was performed using a SYBR Green PCR kit (Applied Biosystems). Total RNA was extracted using Trizol (Invitrogen), as 
Statistical analysis
Data were expressed as the mean with standard deviations. All experiments were performed three times independently and analyzed by Student's t test. Statistical analyses were performed using SPSS17.0 statistics software with P<0.05 as the
Results
To explore the relationship between Nrf2 and BON action, we measured the Nrf2 protein levels in A549 and HepG2 cells. Western blot analysis confirmed that Nrf2 was highly expressed in A549 cells ( Figure 1A, B) , whereas, higher BLH protein levels were detected in HepG2 cells than in A549 cells. To further evaluate the role of Nrf2 in BON susceptibility, we knocked down the expression of Nrf2 protein using the RNA interference technique. Western blot analysis revealed that Nrf2 knockdown was maintained after transfection for 72 h. ROS generation caused by BON treatment leads to apoptosis and cellular senescence in tumor cells [2] . Following knockdown of Nrf2 for 24 h, ROS levels were detected to assess the effect of BON after cells were treated with 20 mol/L BON for 90 min. The level of ROS in the Nrf2 siRNA group was sigtreatment ( Figure 2D ). These results suggest that reducing Nrf2 protein expression attenuates cellular antioxidant function and enhances the action of BON. Nrf2 expression is regulated by p53 and the direct downstream protein p21 [11, 12] . To clarify the effect of p53 on BON susceptibility in A549 cells, we performed p53 knockdown experiments. The protein levels of p53 were significantly reduced after transfection with p53 siRNA for 72 h ( Figure   4A ). However, neither the susceptibility to BON nor DDP was does not play a role in regulating the Nrf2-mediated resistance to BON in A549 cells.
Nrf2 inhibitor, as it suppresses Nrf2 activation independently of KEAP1 via a decrease in Nrf2 mRNA expression [20] . LUT reduced Nrf2 protein expression and showed almost no suppression of cell proliferation at 10 mol/L in A549 cells Figure 5A ), and the synergetic effect of LUT with DDP was greater than that with BON ( Figure 5B ).
bility of A549 cells after Nrf2 knockdown. Following transfection with Nrf2 siRNA for 24 h, the cells were treated with LUT alone or in combination with BON for 48 h (Figure 5C, D) . The synergetic action of LUT with BON disappeared, suggesting that the potentiating action of LUT was dependent on Nrf2.
To further identify the potentiating effect of LUT, apoptotic rates were determined after combined treatment with BON or DDP using Annexin V/PI double staining. In comparison to the proportion of apoptotic cells in those treated with BON or increased in the combination groups ( Figure 5E ), indicating in A549 cells.
GSH serves an important role in maintaining the redox state, drug detoxification, and antioxidant defense. Nrf2 function is connected with GSH due to the direct induction of enzyme in GSH synthesis [26] levels from the two cell lines revealed that GSH content in A549 cells was four times higher than that in HepG2 cells (Fighigher in the A549 cells than that in the HepG2 cells ( Figure  6B ).
Total GSH levels were reduced after the A549 cells were the association between Nrf2 expression with GSH content. Overexpression of Nrf2 with transfected plasmids elevated GSH levels in the HepG2 cells ( Figure 6D ). Altogether, these results suggest that GSH levels are regulated by the Nrf2 protein in both cell lines.
and can deplete cellular GSH levels. A549 cells were treated with different doses of BSO for 24 h, followed by a change in medium and an additional 48 h of culture. Cell viability was BSO failed to suppress cell proliferation ( Figure 7A ) or deplete cellular GSH levels ( Figure 7B ). A549 cells were then exposed -ent concentrations of BON or DDP. The cell survival rates BON to 33.5% in the group treated with BON plus BSO (Figure 7C) , and a similar trend was noted in the DDP treatment group ( Figure 7D) . The results demonstrated that depletion of GSH reduced the resistance of A549 cells to BON.
In contrast, an elevation in GSH levels should increase the resistance to BON. HepG2 cells were pretreated with 4 mmol/L GSH-M for 4 h and then exposed to BON or DDP for 48 h. The sensitivity to BON and DDP decreased after the addition of GSH-M ( Figure 8B , C). 
Discussion
In the present study, we have provided sufficient evidence that Nrf2 mediates resistance to BON, demonstrating that Nrf2 expression can predict BON action in various types of tumors and that BON acts through affecting Nrf2-regulated GSH demonstrate that the Nrf2 signaling pathway influences the action of BON, a bleomycin family member. Although Nrf2 knockdown via RNA interference was previously shown to increase sensitivity to bleomycin in A549 cells [16] , the molecular mechanism connecting Nrf2 protein levels to bleomycin action -ings may aid in predicting tumor sensitivity in BON clinical trials, as well as in clinical applications of bleomycin for precise tumor treatments.
Previous studies have indicated that GSH significantly influences the action of bleomycin. The reduction in GSH induced by BSO treatment has been shown to lead to serious impairments in the DNA repair pathway and an increase in chromosome aberrations in human lymphocytes [23] . Although similar in their pattern of DNA damage induced by radiation, the action of BSO differs from that of bleomycin in high linear energy transfer radiation [24] . In the present study, the addition of exogenous GSH decreased BON action, suggesting a direct molecular indicator for compounds similar to bleomycin. This information is valuable for investigations of other molecular factors that regulate GSH levels, in addition to Nrf2.
Bleomycin is a first-line antitumor antibiotic that is used in the clinic for several types of malignant tumors, such as malignant lymphoma and testicular cancer [27, 28] . However, bleomycin induces pulmonary fibrosis, a major side effect that reduces its clinic application [7] . Furthermore, commercial bleomycin is a mixture of bleomycin A and bleomycin and dose reliability. In contrast, BON has a single chemical structure and a lower induction of pulmonary fibrosis (data not shown), revealing its promise in the treatment of some tumor types in the future. In 2016, a new deglycosylated bleomycin derivative was discovered and was shown to not effects [29] . Therefore, commercial bleomycin will be replaced cancer with fewer side effects. To precisely predict the cellular molecules that impact BON action, a systematic investigation of many factors, including Nrf2 and BLH, is required. Although several reports have -for determining bleomycin action in some types of cancer [3] . BLH protein expression is low in the lungs; however, bleomycin and BON resistance are still found in lung cancer, which may be partly due to high cellular Nrf2 levels. Based on clinical data, approximately 10% of patients develop pulmonary [30] . The development of pulmonary fibrosis involves Nrf2 function as bleomycin has [22] . In addition, pulmonary fibrosis is more severe in the homozygous variant G/G of the BLH gene SNP A1450G in testicular gem cell cancer [31] . Investigations into the connection between BON action and the roles of Nrf2 and BLH are under way in our laboratory.
Recent reports have indicated that Nrf2 plays critical roles in tumor heterogeneity and drug resistance. Nrf2 promotes the survival of cancer stem cells after exposure to DDP [32] . Pancreatic cancers are maintained by Nrf2 through regulating mRNA translation [33] . Therefore, Nrf2 is a potential target for the development of antitumor agents. In the present study, the DDP, consistent with previous results [20, 34] . In summary, Nrf2 mediates the resistance to BON through regulation of antioxidant GSH levels. Nrf2 may be a valuable target for antitumor action and a biomarker for the precise prediction of drug resistance in some types of tumors.
